Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
— Frazier Life Sciences and Lightspeed Venture Partners co-led financing, with significant participation from existing and additional new investors — — Proceeds support further mid-stage clinical development of STX-478, a potentially best-in-class mutant-selective PI3Kα program for…